Rapt Therapeutics

About

Rapt is focused on the discovery and development of novel small-molecule agents to activate the immune system to eradicate cancer.

South San Francisco,California,United States
101 - 250
https://rapt.com/

Highlights

Details

Last Funding Type: Post-IPO Equity
Last Funding Money Raised: $70.50M
Industries: Biotechnology,Health Care,Medical,Pharmaceutical,Therapeutics
Founded date: Mar 4, 2015
Number Of Employee: 101 - 250
Operating Status: Active
Stock Symbol: nasdaq:RAPT
Legal Name: Rapt Therapeutics Inc.
Also Known As: FLX Bio

RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the company is developing highly selective small molecules designed to modulate the critical immune responses underlying these diseases. In its first four years since inception, RAPT has discovered and advanced two unique drug candidates, each targeting C-C motif chemokine receptor 4. The company’s lead oncology drug candidate, FLX475, reached the clinic in just two and a half years with its lead inflammation drug candidate, RPT193, also in the clinic. The company is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1, that are in the discovery stage of development.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

9

$476.20M

Rapt Therapeutics has raised a total of $476.20M in funding over 2 rounds. Their latest funding was raised on Nov 17, 2022 from a Post-IPO Equity round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Nov 17, 2022	Post-IPO Equity	$70.50M	—	—	—	Detail
May 25, 2022	Post-IPO Equity	$50M	1	Redmile Group	—	Detail
Jun 18, 2021	Post-IPO Equity	$143.70M	—	—	—	Detail
Jan 1, 2020	Post-IPO Equity	—	1	—	—	Detail
Oct 30, 2019	IPO	$36M	—	—	—	Detail

Investments

Number of Investments

Number of Lead Investments

17

0

Rapt Therapeutics has made 17 investments. Their most recent investment was on Oct 11, 2022, when Stairwell raised $45M.

Date Company Name	Round	Money Raised	Industry	Lead Investor
Oct 11, 2022 Stairwell	Series B	$45M	Cyber Security	—
Sep 27, 2022 Kumo.AI	Series B	$18M	Artificial Intelligence	—
Aug 9, 2022 CreatorDAO	Seed	$20M	Cryptocurrency	—
Jun 28, 2022 Tenet	Seed	$18M	FinTech	—
Jun 1, 2022 WorkOS	Series B	$80M	Developer APIs	—

Investors

Number of Lead Investors

Number of Investors

1

8

Rapt Therapeutics is funded by 8 investors. Redmile Group and Solasta Ventures are the most recent investors.

Investor Name	Lead Investor	Funding Round
Redmile Group	Yes	Post-IPO Equity
Solasta Ventures	—	Post-IPO Equity
Kleiner Perkins	—	Series C
Regents of the University of California	—	Series C
The Column Group	—	Series C
Topspin Partners	—	Series C
Celgene	—	Series C
GV	—	Series C